secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-281672
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology Q3 net loss $43.8M ($0.57/share); initiates BLA for cretostimogene
------------------------------------------------------------------------------

- Net loss of $43.8M ($0.57 per share) for Q3 2025 vs $20.4M ($0.30) in Q3 2024.
- Cash, cash equivalents and marketable securities $680.3M, sufficient to fund operations into H1 2028.
- Initiated rolling BLA submission to FDA for cretostimogene monotherapy in HR BCG-unresponsive NMIBC.
- R&D expenses $27.9M (up 42% YoY), G&A $23.3M (up 168% YoY) driven by clinical trials and headcount.
- Completed enrollment of Phase 3 PIVOT-006 trial in IR NMIBC 10 months ahead of schedule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/0001193125-25-281672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000119312525281672/ck0001991792-20251114.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-281672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer